Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model
Lab / animal
OA: bronze
CC0
AI-generated summary
Meloxicam, an inhibitor of cyclooxygenase-2, was found to decrease the incidence of ovarian hyperstimulation syndrome in a rat model.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To investigate the effects of selective cyclooxygenase-2 (COX-2) inhibition on the ovarian hyperstimulation syndrome (OHSS) in an experimental model.
DESIGN: Controlled laboratory study.
SETTING: University-affiliated fertility center.
ANIMAL(S): Female Wistar rats.
INTERVENTION(S): Female Wistar rats (22 days old) were divided into four groups: group 1 (control group; n = 10) received 0.1 mL of intraperitoneal (IP) saline from days 22-26; group 2 (mild-stimulated group; n = 10) received 10 IU of pregnant mare serum gonadotropin (PMSG) on day 24 and 10 IU of hCG 48 hours later (day 26); group 3 (OHSS group; n = 10) was given 10 IU of PMSG for 4 consecutive days from day 22 and 30 IU hCG on the fifth day to induce OHSS; group 4 was treated the same as group 3, but received 2 muL (15 mg/mL) of meloxicam 2 hours before the PMSG injection for 4 consecutive days, and 2 hours before the hCG injection on the fifth day. All groups were killed on day 26.
MAIN OUTCOME MEASURE(S): Number of antral and luteinized follicles, ovarian weight, semiquantitative vascular endothelial growth factor (VEGF) and COX-2 immunohistochemistry.
RESULT(S): There were no differences in the ovarian weight between groups 1 and 2. Group 3 showed significantly increased ovarian weight that was suppressed, in group 4, by meloxicam. There was no difference in the number of antral follicles among the four groups. In the mild-stimulated and OHSS groups, the granulosa cells (GC) of preovulatory follicles and the stromal cells showed intense VEGF immunoreactivity. The ovaries from the meloxicam-treated group showed less immunoreactivity than the OHSS group, indicating diminished VEGF expression associated with meloxicam treatment. Group 3 (OHSS group) showed increased COX-2 immunoreactivity that was diminished in the meloxicam-treated group. Meloxicam treatment did not affect the hormone-induced increase in serum E(2) levels seen in OHSS rats.
CONCLUSION(S): Our results in a rat model suggest that meloxicam has a beneficial effect on OHSS by reducing the increases in ovarian weight and VEGF expression associated with OHSS. These effects may be mediated by the COX-2 inhibitory capacity of meloxicam.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis 2006
- The potential danger of COX-2 inhibitors 2004
- Effects of selective inhibition of cyclooxygenase and lipooxygenase pathways in follicle rupture and ovulation in the rat 2006
References (30)
- Effects of selective inhibition of cyclooxygenase and lipooxygenase pathways in follicle rupture and ovulation in the rat via openalex
- Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis via openalex
- The potential danger of COX-2 inhibitors via openalex
- doi:10.1016/s0092-8674(00)81433-6 via openalex
- doi:10.1177/0091270006289483 via openalex
- doi:10.1016/s0015-0282(97)81520-8 via openalex
- doi:10.3109/08977199509003209 via openalex
- doi:10.1006/bbrc.1996.1355 via openalex
- doi:10.1016/j.fertnstert.2004.06.057 via openalex
- doi:10.1210/endo.140.6.6715 via openalex
- doi:10.1111/j.1471-0528.1995.tb10840.x via openalex
- doi:10.1507/endocrj.50.515 via openalex
- doi:10.1262/jrd.51.161 via openalex
- doi:10.1111/j.1525-1438.2006.00477.x via openalex
- doi:10.2165/00003495-199651030-00007 via openalex
- doi:10.1016/s0010-7824(01)00207-4 via openalex
- doi:10.3892/ijmm.5.5.447 via openalex
- W6670431718 via openalex
- doi:10.1016/s0015-0282(97)81908-5 via openalex
- doi:10.1016/s0015-0282(16)43508-9 via openalex
- doi:10.1074/jbc.m201095200 via openalex
- doi:10.1095/biolreprod.102.010801 via openalex
- doi:10.1038/nrd1034 via openalex
- doi:10.1210/endo.142.10.8418 via openalex
- doi:10.1095/biolreprod60.2.398 via openalex
- doi:10.1136/ijgc-00009577-200602001-00040 via openalex
- doi:10.1016/s0022-5347(05)67321-1 via openalex
- doi:10.1016/j.fertnstert.2004.03.053 via openalex
- doi:10.1210/mend-5-12-1806 via openalex
- doi:10.1210/en.2002-220204 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T06:10:27.824888+00:00
- pubmed
- last seen: 2026-10-08T21:05:01.267406+00:00
License: CC0
· commercial use OK